STU3 Candidate

This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4 R3

Plandefinition-example-kdn5-simplified

This is the narrative for the resource. See also the XML or JSON format. This example conforms to the profile PlanDefinition.

National Comprehensive Cancer Network

Chemotherapy Order Template

Kidney Cancer

Gemcitabine/CARBOplatin

 KDN5

INDICATION:

Metastatic or Relapsed – Collecting Duct/Medullary Subtypes

REFERENCES:

  1. NCCN Guidelines® for Kidney Cancer. V.3.2015.
  2. Oudard S, et al. J Urol. 2007;177(5):1698-702. a

NCCN SUPPORTIVE CARE:

  1. Emetic Risk:
    Day 1 Moderate
    Day 8 Low
  2. Fever Neutropenia Risk:
    Refer to NCCN Guidelines for Myeloid Growth Factors. V.2.2014

CHEMOTHERAPY REGIMEN

21-day cycle for 6 cycles

  • Gemcitabine 1250 mg/m2 IV over 30 minutes on Days 1 and 8
  • CARBOplatin AUC 5 IV over 30 minutes on Day 1

 

 

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.